CTX-471

CTX-471 is a fully human monoclonal antibody of CD137 . CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K d values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer In Vitro CTX-471 (5-500 nM) has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K d values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 binds to a unique epitope on CD137. CTX-471 (0.1-100 nM; 1, 10 μg/mL; 3 days) increases IFN-y production by human T cells in an Fcy receptor-dependent (FcyR-dependent) manner in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CTX-471 (i.p.; 150 μg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors. CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c mice Dosage: 150 μg; 10-80 mg/kg Administration: i.p., on days 6, 9, 12, 19 and 26( or on days 7, 10, 13, 20, and 27 or on days 0, 3, 6, and 9); i.v., on days 0, 7, 14, and 21 Result: Required T and NK cells, as well as FcγR engagement to achieve its efficacy. Do not induce hepatic inflammation. Form:Liquid IC50& Target:Kd for CD137: 50 nM (human),61 nM (cynomolgus macaque),748 nM (mouse)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet